A computational method for computing an Alzheimer's disease progression score; experiments and validation with the ADNI data set

Alzheimer's Disease Neuroimaging Initiative

Research output: Contribution to journalArticle

Abstract

Understanding the time-dependent changes of biomarkers related to Alzheimer's disease (AD) is a key to assessing disease progression and measuring the outcomes of disease-modifying therapies. In this article, we validate an AD progression score model which uses multiple biomarkers to quantify the AD progression of subjects following 3 assumptions: (1) there is a unique disease progression for all subjects; (2) each subject has a different age of onset and rate of progression; and (3) each biomarker is sigmoidal as a function of disease progression. Fitting the parameters of this model is a challenging problem which we approach using an alternating least squares optimization algorithm. To validate this optimization scheme under realistic conditions, we use the Alzheimer's Disease Neuroimaging Initiative cohort. With the help of Monte Carlo simulations, we show that most of the global parameters of the model are tightly estimated, thus enabling an ordering of the biomarkers that fit the model well, ordered as: the Rey auditory verbal learning test with 30minutes delay, the sum of the 2 lateral hippocampal volumes divided by the intracranial volume, followed (by the clinical dementia rating sum of boxes score and the mini-mental state examination score) in no particular order and at last the AD assessment scale-cognitive subscale.

Original languageEnglish (US)
Pages (from-to)S178-S184
JournalNeurobiology of aging
Volume36
Issue numberS1
DOIs
StatePublished - Jan 1 2015

Keywords

  • Alzheimer's disease
  • Biomarkers
  • Progression score
  • Sampling from the residuals

ASJC Scopus subject areas

  • Neuroscience(all)
  • Aging
  • Clinical Neurology
  • Developmental Biology
  • Geriatrics and Gerontology

Fingerprint Dive into the research topics of 'A computational method for computing an Alzheimer's disease progression score; experiments and validation with the ADNI data set'. Together they form a unique fingerprint.

  • Cite this